'What Is Microbiologic Success?': Rare Lung Infection Is Microcosm Of Antibiotic Development Challenges

FDA is working hard on expanded access program for patients with non-tuberculous mycobacterial (NTM) lung infections; there is no approved drug for the condition in part because of the difficulty in defining trial endpoints.